J&J reported second quarter earnings Tuesday. The company is under scrutiny by investors as it faces drug patent cliffs.

Johnson & Johnson (JNJ) on Wednesday lifted its full-year projections and reported second quarter results that beat estimates. The medical device and drug maker posted adjusted earnings per share of ...

If you look at the history of the S&P 500 ( ^GSPC -0.40%) index, dividend stocks have played a significant role in ...

Plus, Adelita Grijalva wins the Democratic primary in the race for a House seat in Arizona. The seat was left vacant by her ...

House Speaker Mike Johnson urged Attorney General Pam Bondi to "come forward and explain" the administration's handling of ...

J&J boosted its annual outlook, after posting better-than-expected quarterly profit and sales. Shares rose over 1% in ...

Report is The Hill’s a.m. newsletter. Subscribe here or using the box below: In today’s issue: ▪ Epstein uproar splits GOP ▪ What to expect at Hill Nation Summit ▪ The Bidens ...

Away from the razzmatazz of the red carpet, Hollywood’s A-list are often spotted enjoying a wholesome Sunday at Studio City ...

Johnson & Johnson boosted its full-year outlook as it posted better-than-expected profit and sales in the second quarter. The healthcare-products company said Tuesday it now expects adjusted per-share ...

The airspace above Vancouver International Airport had to be shut down on Tuesday after someone “hijacked” a small plane. The ...

Johnson & Johnson expects full-year earnings in the range of $10.80 to $10.90 per share, with revenue in the range of $93.2 billion to $93.6 billion. This story was generated by Automated Insights ( ...

Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the average analyst EPS estimate compiled by FactSet of $2.68.